Table 5.

Quotes from interviews illustrating function 6 – Creation of Legitimacy.

Quote number (#)	Quote and interviewee
13	“The warp speed project in the US skipped over the whole consistency lot and postponed it until later in order to get data quicker. But the normal thing [to do] is to make three consistency lots of scale, or scale or something close to it, and test those in the phase III trial, which was not done in the US this time. And nothing terrible seems to have happened. So, there are some barriers that might be reduced in scope. (…) And it doesn't sound like much, but you're talking about saving like three to four years off a development timeline.” – Respondent #11 – NGO
14	“An important barrier is GMO regulation in Europe, while GMOs are safe by design. (…) These regulations were lifted during the pandemic. I hope the public will pressurize this lifting of regulations, because it will not be coming from policy makers.” – Respondent #7 – Academia
15	“We have a very neurotically coordinated regulatory approval system, and pharmaceutical companies have followed the increasingly stricter guidelines. Therefore, this system now keeps itself in place in its own complexity. (…) It has become so complicated to perform clinical studies with the vast amount of data that has to be gathered, that the CRO-market has become a market on its own, where incredible amounts of profit are being made. So, companies and regulators keep this system in place, but it remains questionable what the usefulness of this system is.” – Respondent #5 – Governmental funding agency